Seeking a home for a pet, part 3: Emerging applications of positron emission tomography imaging in the management of patients with lung cancer

Chest

Volumn 126, Issue 5, 2004, Pages 1656-1666

  Detterbeck, Frank C ^a,c   Vansteenkiste, Johan F ^b   Morris, David E ^a   Dooms, Christophe A ^b   Khandani, Amir H ^a   Socinski, Mark A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Lung cancer; Positron emission tomography

Indexed keywords

ANTIINFECTIVE AGENT;

CANCER STAGING; CHEMOTHERAPY; HUMAN; LUNG CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 8744293064     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.5.1656     Document Type: Review

References (77)

1. Detterbeck F, Falen S, Rivera M, et al. Seeking a home for a PET, Part 1: Defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses. Chest 2004; 125:2294-2299
2. Detterbeck F, Falen S, Rivera M, et al. Seeking a home for a PET, Part 2: Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer. Chest 2004; 125:2300-2308
3. Higashi K, Seki H, Ueda T, et al. FDG uptake of non-small cell lung cancer: correlation with cell proliferation and cellular density [abstract]. J Nucl Med 1998; 39:247P-248P
4. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000; 6:3837-3844
5. Higashi K, Ueda Y, Yagishita M, et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 2000; 41:85-92
6. Duhaylongsod FG, Lowe VJ, Patz EF Jr, et al. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995; 60:1348-1352
7. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002; 43:39-45
8. Sasaki R, Komaki R, Macapinlac H, et al. SUV by FDG-PET predicts outcome of non-small cell lung cancer [abstract]. Int J Radiat Oncol Biol Phys 2003; 57:S166
9. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999; 17:3201-3206
10. Jeong HJ, Min JJ, Park JM, et al. Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 2002; 23:865-870
11. Ahuja V, Coleman RE, Herndon J, et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998; 83:918-924
12. 18F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 2000; 18:425-428
13. Weber WA, Ziegler SI, Thodtmann R, et al. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999; 40:1771-1777
14. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995; 36:1836-1839
15. Rosell R, Gómez-Codina J, Camps C, et al. Presectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999; 47:7-14
16. Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21:1-6
17. Albain K, Scott C, Rusch V, et al. Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93-09) [abstract]. Proc Am Soc Clin Oncol 2003; 22:621
18. Detterbeck FC, Socinski MA. Induction therapy and surgery for I-IIIa, b non-small cell lung cancer. In: Detterbeck FC, Rivera MP, Socinski MA, et al, eds. Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician. Philadelphia, PA: WB Saunders, 2001; 257-266
19. Cerfolio RJ, Ojha B, Mukherjee S, et al. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg 2003; 125:938-944
20. Port JL, Kent MS, Korst RJ, et al. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg 2004; 77:254-259
21. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. Ann Oncol 1998; 9:1193-1198
22. Ryu JS, Choi NC, Fischman AJ, et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 2002; 35:179-187
23. Vansteenkiste J, Stroobants SG, Hoekstra CJ, et al. 18fluoro-2- deoxyglucose positron emission tomography (PET) in the assessment of induction chemotherapy (IC) in stage IIIA-N2 NSCLC: a multi-center prospective study [abstract]. Proc Am Soc Clin Oncol 2001; 20:13A
24. Akhurst T, Downey RJ, Ginsberg MS, et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg 2002; 72:259-266
25. Choi NC, Fischman AJ, Niemierko A, et al. Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 54:1024-1035
26. Detterbeck FC, Jones DR, Parker LA Jr. Intrathoracic staging. In: Detterbeck FC, Rivera MP, Socinski MA, et al, eds. Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician. Philadelphia, PA: WB Saunders, 2001; 73-93
27. Griesinger F, Glaetzner T, Schmidberger H, et al. FDG-PET response predicts OS and DFS after induction chemotherapy (docetaxel (D)/carboplatin (O)/erythropoietin (Epo) in stage III non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 2003; 22:640
28. Patz EF Jr, Connolly J, Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR Am J Roentgenol 2000; 174:769-774
29. 18-F FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification. J Nucl Med 2001; 42:1605-1613
30. MacManus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003; 21:1285-1292
31. Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000; 18:1689-1695
32. Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000; 18:1676-1688
33. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19:3058-3065
34. Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004; 22:900-908
35. Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91:4464-4471
36. Schulte M, Brecht-Krauss D, Werner M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 1999; 40:1637-1643
37. Brucher BL, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001; 233:300-309
38. Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002; 13:361-368
39. Socinski MA, Morris DE, Masters GA, et al. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003; 123:226S-243S
40. Socinski MA. Chemotherapy for stage IV NSCLC. In: Detterbeck FA, Rivera MP, Socinski MA, et al, eds. Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician. Philadelphia, PA: Saunders, 2001; 307-325
41. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003; 21:2651-2657
42. Minn H, Zasadny KR, Quint LE, et al. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 1995; 196:167-173
43. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
44. Hoekstra CJ, Hoekstra OS, Stroobants SG, et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 2002; 43:1304-1309
45. MacManus MR, Hicks R, Fisher R, et al. FDG-PET-detected extracranial metastasis in patients with non-small cell lung cancer undergoing staging for surgery or radical radiotherapy: survival correlates with metastatic disease burden. Acta Oncol 2003; 42:48-54
46. Frank A, Lefkowitz D, Jaeger S, et al. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 1995; 32:1495-1512
47. Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 2001; 19:127-136
48. Socinski MA, Morris DE, Halle J, et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA/B non-small cell lung cancer: a dose escalation phase I trial. J Clin Oncol 2004 (in press)
49. Rosenzweig KE, Dladla N, Schindelheim R, et al. Three-dimensional conformal radiation therapy (3D-CRT) for early-stage non-small-cell lung cancer. Clin Lung Cancer 2001; 3:141-144
50. Nestle U, Walter K, Schmidt S, et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 1999; 44:593-597
51. Schmucking M, Baum RP, Griesinger F, et al. Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning. Recent Results Cancer Res 2003; 162:195-202
52. 18F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 2001; 19:111-118
53. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 2000; 55:317-324
54. Hebert ME, Lowe VJ, Hoffman JM, et al. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. Am J Clin Oncol 1996; 19:416-421
55. Erdi YE, Macapinlac H, Rosenzweig KE, et al. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 2000; 27:861-866
56. Mah K, Caldwell CB, Ung YC, et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 2002; 52:339-350
57. Nehmen SA, Erdi YE, Rosenzweig KE, et al. Reduction of respiratory motion artifacts in PET imaging of lung cancer by respiratory correlated dynamic PET: methodology and comparison with respiratory gated PET. J Nucl Med 2003; 44:1644-1648
58. Morris DE, Rosenman JG, Halle JS, et al. Induction chemotherapy followed by dose-escalated thoracic 3-dimensional conformal radiation therapy to 90 Gy with concurrent chemotherapy in stage IIIA/B non-small cell lung cancer: a phase radiation dose escalation trial. Int J Radiat Oncol Biol Phys 2003; 57:S138-S139
59. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human non-small cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995; 33:391-398
60. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348: 2500-2507
61. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Chest 1997; 112:1480-1486
62. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? Eur J Nucl Med 1998; 25:1495-1501
63. Magnani P, Carretta A, Rizzo G, et al. FDG/PET and spiral CT image fusion for mediastinal lymph node assessment of non-small cell lung cancer patients. J Cardiovasc Surg (Torino) 1999; 40:741-748
64. Weng E, Tran L, Rege S, et al. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer. Am J Clin Oncol 2000; 23:47-52
65. Fritscher-Ravens A, Bohuslavizki KH, Brandt L, et al. Mediastinal lymph node involvement in potentially resectable lung cancer: comparison of CT, positron emission tomography, and endoscopic ultrasonography with and without fine-needle aspiration. Chest 2003; 123:442-451
66. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 2003; 229:526-533
67. Aquino SL, Asmuth JC, Moore RH, et al. Improved image interpretation with registered thoracic CT and positron emission tomography data sets. AJR Am J Roentgenol 2002; 178:939-944
68. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998; 16:2142-2149
69. Fischer BM, Mortensen J, Højgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol 2001; 2:659-666
70. Toloza EM, Harpole L, McCrory D. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003; 123:137S-146S
71. Vogel WV, Oyen WJ, Barentsz JO, et al. PET/CT: panacea, redundancy, or something in between? J Nucl Med 2004; 45(Suppl 1):15S-24S
72. Nehmeh SA, Erdi YE, Ling CC, et al. Effect of respiratory gating on reducing lung motion artifacts in PET imaging of lung cancer. Med Phys 2002; 29:366-371
73. Buck AK, Schirrmeister H, Hetzel M, et al. 3-Deoxy-3-[(18)F] fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002; 62:3331-3334
74. Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothyinidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunoblstochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002; 8:3315-3323
75. Buck AK, Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003; 44:1426-1431
76. Zanzonico P, O'Donoghue J, Chapman JD, et al. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging 2004; 31:117-128
77. Chao KS, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001; 49:1171-1182